The DOI matches its Crossref record.
Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I‐meta‐iodobenzylguanidine (131I‐mIBG)
Abstract
OBJECTIVE Meta‐iodo‐benzyl‐guanidine labelled with 131‐iodine (131 I‐mIBG) has been used extensively for imaging tumours originating from the neural crest but experience with its therapeutic use is limited, particularly for non‐catecholamine secreting tumours. In order to assess the therapeutic response and potential adverse effects of the therapeutic administration of 131 I‐mIBG, we have reviewed all patients who had received this form of treatment in our department. DESIGN Retrospective analysis of the case notes of patients with neuroendocrine tumours who received treatment with 131 I‐mIBG and were followed‐up according to a defined protocol in a given time frame. PATIENTS Thirty‐seven patients (18 with metastatic carcinoid tumours, 8 metastatic phaeochromocytoma, 7 metastatic paraganglioma and 4 metastatic medullary carcinoma of the thyroid) treated with 131 I‐mIBG over a 15‐year period were included in this analysis. MEASUREMENTS The symptomatic, hormonal and tumoural responses before and after 131 I‐mIBG therapy over a median follow‐up duration of 32 months (range 5–180 months) were recorded. Of the 37 patients (22 males; median age 51 years, range 18–81 years), 15 were treated with 131 I‐mIBG alone whereas the other 22 received additional therapy. RESULTS A total of 116 therapeutic 131 I‐mIBG doses were administered [mean cumulative dose 592 mCi (21·9 GBq); range 200–1592 mCi (7·4–58·9 GBq)]. None of the patients showed a complete tumour response. However, 82% of patients treated with 131 I‐mIBG alone and 84% who received additional therapy showed stable disease over the period of follow‐up. Overall survival during the period of the study was 71%. The overall 5‐year survival rate was 85% (95% confidence interval, 72–99%) for all patients and 78% (95% confidence interval, 55–100%) for the carcinoid group alone, according to Kaplan–Meier analysis. Symptomatic control was achieved in all the patients treated with 131 I‐mIBG alone, and in 72% of those receiving additional therapy. Hormonal control was noted in 50% and 57% of patients, respectively. 131 I‐mIBG therapy was safe and well tolerated. Serious side‐effects necessitating the termination of 131 I‐mIBG therapy were seen in only 2 of our patients. CONCLUSIONS 131 I‐mIBG therapy produces symptomatic and hormonal improvement and moderate tumour regression/stabilization in patients with metastatic neuroendocrine tumours with minimal adverse effects. It may be a valuable alternative or additional therapeutic option to the currently available conventional treatment modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Self-citationCurrent Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
Pheochromocytoma: recommendations for clinical practice from the First International Symposium
Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S. R., Gimenez-Roqueplo, A.-P., Grossman, A. B., Kimura, N., Mannelli, M., McNicol, A. M., & Tischler, A. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0396 · Cited by 680
Self-citationThe diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Self-citationA review on the clinical uses of SPECT/CT
Mariani, G., Bruselli, L., Kuwert, T., Kim, E. E., Flotats, A., Israel, O., Dondi, M., & Watanabe, N. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1390-8 · Cited by 438
Metadata
- Authors
- Mukherjee, J. J., Kaltsas, G. A., Islam, N., Plowman, P. N., Foley, R., Hikmat, J., Britton, K. E., Jenkins, P. J., Chew, S. L., Monson, J. P., Besser, G. M., & Grossman, A. B.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2001-07
- Volume
- 55
- Issue
- 1
- Pages
- 47-60
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2055454912
- Cited by
- 167
- References
- 0
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I‐meta‐iodobenzylguanidine (131I‐mIBG). https://app.cochat.ai/papers/10.1046/j.1365-2265.2001.01309.x
- The paper
- Mukherjee, J. J., Kaltsas, G. A., Islam, N., Plowman, P. N., Foley, R., Hikmat, J., Britton, K. E., Jenkins, P. J., Chew, S. L., Monson, J. P., Besser, G. M., & Grossman, A. B. (2001). Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I‐meta‐iodobenzylguanidine (131I‐mIBG). Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2001.01309.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.